BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

1:04 PM
 | 
Nov 02, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MyoKardia's heart failure candidate shows proof of mechanism in Phase Ia

MyoKardia Inc. (NASDAQ:MYOK) reported data from a Phase Ia trial in healthy volunteers showing that heart failure candidate MYK-491 increased cardiac contractility by 5-20% across multiple echocardiographic parameters with minimal effect on diastolic function. The Australian trial enrolled...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >